

## Contents

<b>Introduction</b> , L. Minasian, A. O'Mara	1
<b>Translating the Science of Patient-Reported Outcomes Assessment Into Clinical Practice</b> , D. Osoba	5
<b>Outcomes Research in Cancer Symptom Management Trials: The Radiation Therapy Oncology Group (RTOG) Conceptual Model</b> , D.W. Bruner	12
<b>Symptom Burden: Multiple Symptoms and Their Impact as Patient-Reported Outcomes</b> , C.S. Cleeland	16
<b>Differences in What Quality-of-Life Instruments Measure</b> , C.E. Ferrans	22
<b>Challenges to Use of Health-Related Quality of Life for Food and Drug Administration Approval of Anticancer Products</b> , E.P. Rock, J.A. Scott, D.L. Kennedy, R. Sridhara, R. Pazdur, L.B. Burke	27
<b>Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data?</b> C.M. Moinpour, G.W. Donaldson, M.W. Redman	31
<b>Conceptual Issues in Symptom Clusters Research and Their Implications for Quality-of-Life Assessment in Patients With Cancer</b> , C. Miaskowski, B.E. Aouizerat, M. Dodd, B. Cooper	39
<b>Health-Related Quality of Life Measurement in Symptom Management Trials</b> , P.A. Ganz, P.J. Goodwin	47
<b>Should Health-Related Quality of Life Be Measured in Cancer Symptom Management Clinical Trials? Lessons Learned Using the Functional Assessment of Cancer Therapy</b> , D. Cella, L. Wagner, J. Cashy, T.A. Hensing, S. Yount, R.C. Lilenbaum	53